Primary endpoint met in both US trials and positive ex-US EBITDA excl. one-offs in Q4 Fourth quarter 2024Net sales for the quarter totalled MSEK 49.2 (44.5), equivalent to an increase of 10% compared ...

SEMINOLE, FL / ACCESS Newswire / February 12, 2025 / For many, visiting the dentist can be a stressful and overwhelming ...

Sedana Medical AB (publ) announces that its second pivotal US trial INSPiRE-ICU 2 has met its primary endpoint, and hence established non-inferiority of inhaled sedation with isoflurane compared with ...